(Q28240897)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21677639%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

MDMA

0 references

title

The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21677639%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21677639%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Marius Hoener

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21677639%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Jörg Huwyler

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21677639%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

C M Hysek

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21677639%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

M Ineichen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21677639%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

E Grouzmann

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21677639%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

R Brenneisen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21677639%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

M E Liechti

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21677639%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

language of work or name

English

0 references

publication date

15 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21677639%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21677639%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

90

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21677639%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21677639%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

246-255

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21677639%20AND%20SRC:MED&resulttype=core&format=json

The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study

5 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038/CLPT.2011.78

Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/CLPT.2011.78

Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/CLPT.2011.78

The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/CLPT.2011.78

Vascular actions of MDMA involve alpha1 and alpha2-adrenoceptors in the anaesthetized rat

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/CLPT.2011.78

Norepinephrine and stimulant addiction

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/CLPT.2011.78

Is ecstasy an "empathogen"? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/CLPT.2011.78

Psychometric evaluation of the altered states of consciousness rating scale (OAV)

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/CLPT.2011.78

Gender differences in the subjective effects of MDMA.

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Cannabis coadministration potentiates the effects of "ecstasy" on heart rate and temperature in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Evidence for noncompetitive modulation of substrate-induced serotonin release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Serotonin-transporter mediated efflux: a pharmacological analysis of amphetamines and non-amphetamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

High dose pimozide does not block amphetamine-induced euphoria in normal volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Effects of a beta-blocker on the cardiovascular response to MDMA (Ecstasy).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Carvedilol reverses hyperthermia and attenuates rhabdomyolysis induced by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) in an animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Alpha1-adrenergic receptors mediate the locomotor response to systemic administration of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Blockade of noradrenaline transport abolishes 4-methylthioamphetamine-induced contraction of the rat aorta in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Safety, tolerability and subject-rated effects of acute intranasal cocaine administration during atomoxetine maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Atomoxetine attenuates dextroamphetamine effects in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Non-linear pharmacokinetics of MDMA ('ecstasy') in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Amphetamine induces dopamine efflux through a dopamine transporter channel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Cognitive enhancement as a pharmacotherapy target for stimulant addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Acute norepinephrine reuptake inhibition decreases performance in normal and high ambient temperature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

The standardized psychometric assessment of altered states of consciousness (ASCs) in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

A Comparison of Aripiprazole, Methylphenidate, and Placebo for Amphetamine Dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.78

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2011.78

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21677639%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017